Abera Bioscience AB (NGM:ABERA)
Sweden
· Delayed Price · Currency is SEK 7.30
-0.85 (-10.43%)
At close: May 13, 2025
Abera Bioscience AB Income Statement
Financials in millions SEK. Fiscal year is January - December.
Millions SEK. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2017 - 2019 |
|---|---|---|---|---|---|---|---|
Period Ending | Mar '25 Mar 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2017 - 2019 |
| Other Revenue | 16.15 | 14.85 | 2.52 | 1.79 | 1.18 | 0.76 | Upgrade
|
| Revenue | 16.15 | 14.85 | 2.52 | 1.79 | 1.18 | 0.76 | Upgrade
|
| Revenue Growth (YoY) | 236.95% | 488.13% | 41.21% | 51.78% | 55.92% | -49.67% | Upgrade
|
| Gross Profit | 16.15 | 14.85 | 2.52 | 1.79 | 1.18 | 0.76 | Upgrade
|
| Selling, General & Admin | 16.66 | 15.72 | 19.35 | 21.19 | 10.34 | 4.39 | Upgrade
|
| Other Operating Expenses | 0.15 | 0.18 | 0.09 | 0.05 | 0.02 | 0.06 | Upgrade
|
| Operating Expenses | 16.91 | 15.97 | 19.45 | 21.24 | 10.35 | 4.46 | Upgrade
|
| Operating Income | -0.76 | -1.12 | -16.92 | -19.45 | -9.18 | -3.7 | Upgrade
|
| Interest Expense | -0 | -0 | -0 | - | -0 | - | Upgrade
|
| Interest & Investment Income | 0.04 | 0.02 | 0.08 | 0.01 | - | - | Upgrade
|
| Currency Exchange Gain (Loss) | - | - | 0.12 | 0.06 | 0.01 | 0.06 | Upgrade
|
| Other Non Operating Income (Expenses) | -0 | -0 | - | - | - | - | Upgrade
|
| Pretax Income | -0.73 | -1.1 | -16.72 | -19.38 | -9.17 | -3.64 | Upgrade
|
| Net Income | -0.73 | -1.1 | -16.72 | -19.38 | -9.17 | -3.64 | Upgrade
|
| Net Income to Common | -0.73 | -1.1 | -16.72 | -19.38 | -9.17 | -3.64 | Upgrade
|
| Shares Outstanding (Basic) | - | 16 | 13 | 12 | 10 | 7 | Upgrade
|
| Shares Outstanding (Diluted) | - | 16 | 13 | 12 | 10 | 7 | Upgrade
|
| Shares Change (YoY) | - | 18.44% | 13.64% | 14.64% | 45.39% | 200.47% | Upgrade
|
| EPS (Basic) | - | -0.07 | -1.26 | -1.66 | -0.90 | -0.52 | Upgrade
|
| EPS (Diluted) | - | -0.07 | -1.26 | -1.66 | -0.90 | -0.52 | Upgrade
|
| Free Cash Flow | -1.28 | -1.33 | -17.71 | -19.69 | -9.68 | -2.75 | Upgrade
|
| Free Cash Flow Per Share | - | -0.09 | -1.33 | -1.69 | -0.95 | -0.39 | Upgrade
|
| Gross Margin | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | Upgrade
|
| Operating Margin | -4.72% | -7.54% | -670.22% | -1088.19% | -779.01% | -490.10% | Upgrade
|
| Profit Margin | -4.51% | -7.41% | -662.16% | -1084.01% | -778.09% | -482.12% | Upgrade
|
| Free Cash Flow Margin | -7.95% | -8.95% | -701.43% | -1101.46% | -821.76% | -363.90% | Upgrade
|
| EBITDA | - | -1.06 | - | - | - | - | Upgrade
|
| EBITDA Margin | - | -7.12% | - | - | - | - | Upgrade
|
| D&A For EBITDA | - | 0.06 | - | - | - | - | Upgrade
|
| EBIT | -0.76 | -1.12 | -16.92 | -19.45 | -9.18 | -3.7 | Upgrade
|
| EBIT Margin | -4.72% | -7.54% | - | - | - | - | Upgrade
|
| Revenue as Reported | 16.15 | 14.85 | 2.65 | 1.85 | 1.19 | 0.82 | Upgrade
|
Source: S&P Global Market Intelligence. Standard template. Financial Sources.